Vertex Expands Casgevy Approval to Children Aged Five in the UK

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has extended the marketing authorisation for Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel), allowing eligible children aged five years and older with severe sickle cell disease (SCD) or transfusion-dependent -thalassemia (TDT) to receive the CRISPR-based gene-editing therapy. Granted on 29 October 2026, the regulatory decision lowers the previously authorized age threshold from 12 years, expanding access to a transformative treatment option for younger pediatric patients suffering from serious inherited blood disorders.

Disease Burden and Clinical Rationale in Younger Patients

Severe sickle cell disease and transfusion-dependent -thalassemia are inherited monogenic conditions caused by genetic mutations affecting haemoglobin, the essential protein responsible for oxygen transport in red blood cells. In sickle cell disease, abnormal haemoglobin polymerization causes red blood cells to assume a rigid, sickle-like morphology. These defective erythrocytes obstruct microvascular blood flow, precipitating recurrent and debilitating vaso-occlusive pain crises, chronic anaemia, progressive organ damage, and a markedly heightened risk of severe infections.

In contrast, -thalassemia is characterized by reduced or absent production of the beta-globin protein chain, impairing effective haemoglobin synthesis and causing severe chronic anaemia. Patients with transfusion-dependent disease require lifelong, regular red blood cell transfusions every three to five weeks, alongside continuous medical interventions such as iron chelation therapy to manage iron overload and transfusion-related complications. Expanding Casgevy’s authorisation to children aged five and older introduces gene-editing interventions at a significantly earlier stage of life, offering eligible patients a potentially curative alternative to lifelong disease management.

Mechanism of Action: Target Gene Editing via CRISPR-Cas9

Casgevy utilizes ex vivo CRISPR-Cas9 gene-editing technology to genetically modify a patient’s own haematopoietic stem cells. The therapeutic construct specifically targets and disrupts the erythroid-specific enhancer region of the BCL11A gene. Under normal physiological conditions after birth, the BCL11A transcription factor acts as a repressor that shuts off the production of fetal haemoglobin (HbF). By knocking down this erythroid enhancer, Casgevy reactivates the endogenous production of  in developing red blood cells.

Because fetal haemoglobin naturally binds oxygen without being affected by the structural abnormalities or globin chain deficiencies responsible for SCD and -thalassemia, elevated  levels functionally compensate for the defective adult haemoglobin. The multi-step administration process involves harvesting autologous haematopoietic stem cells from the patient, editing them outside the body in a specialized manufacturing facility, and reinfusing the modified cells back into the patient. Prior to infusion, patients must undergo myeloablative conditioning chemotherapy to clear space within the bone marrow niche. Following reinfusion, the edited stem cells engraft within the bone marrow and continuously generate red blood cells containing high levels of protective fetal haemoglobin.

Treatment Process, Safety Profile, and Regulatory Outlook

Despite its potential as a one-time therapeutic solution, Casgevy represents a intensive clinical procedure. Patients require myeloablative conditioning prior to receiving their modified stem cells and typically undergo prolonged hospitalization while the engineered cells engraft and restore normal haematopoiesis. The MHRA highlighted several associated adverse events, including nausea, fatigue, fever, and a temporary increase in infection risk stemming from chemotherapy-induced immunosuppression. Consequently, pediatric eligibility depends on comprehensive individual clinical evaluations to ensure younger children possess the functional capacity to tolerate myeloablative conditioning and the post-transplantation recovery phase.

Julian Beach, MHRA Executive Director of Operations, noted that the authorisation extension followed a rigorous assessment of the available evidence supporting Casgevy’s safety, quality, and efficacy. He underscored the clinical significance of bringing gene editing to eligible children from five years of age while confirming that the regulator will maintain strict post-approval safety monitoring. Ultimately, the decision marks another key milestone in the clinical implementation of CRISPR-based medicines. However, due to the complex logistics of autologous cell collection, specialized manufacturing, myeloablation, and post-infusion monitoring, real-world access will depend on specialized treatment centers equipped with advanced cellular therapy and bone marrow transplantation infrastructure.

Reference

MHRA approves gene-editing treatment for children aged five and over with serious inherited blood disorders, MHRA, 30 October 2026.